NDATOPICALSOLUTION
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
KERYDIN (tavaborole) by R-Pharm US is protein synthesis inhibitors [moa]. Approved for onychomycosis. First approved in 2014.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERYDIN (tavaborole) is a topical antifungal solution approved in 2014 for onychomycosis (fungal nail infection). It works by inhibiting fungal protein synthesis, targeting the causative dermatophytes at the nail site. The solution formulation allows direct application to affected nails with minimal systemic absorption.
$0.019MPart D
PeakDeclining
KERYDIN is in peak lifecycle but facing significant competitive pressure (30% competitive intensity); team size and investment likely modest relative to market-leading alternatives.
Mechanism of Action
Protein Synthesis Inhibitors
Indications (1)
Clinical Trials (1)
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Started Oct 2015
55 enrolled
OnychomycosisTinea Unguium
Career Relevance
KERYDIN offers careers in a mature, competitive oncology-adjacent specialty market with modest growth potential and significant pricing/reimbursement headwinds. Roles are likely focused on market defense, payer negotiation, and physician engagement rather than launch or expansion.
Worked on KERYDIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.